Trials / Conditions / Diarrhea-predominant Irritable Bowel Syndrome

Diarrhea-predominant Irritable Bowel Syndrome

29 registered clinical trials studyying Diarrhea-predominant Irritable Bowel Syndrome — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Sy NCT07000383	University Medical Center Ho Chi Minh City (UMC)	N/A
Completed	Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS NCT06346847	A-Mansia Biotech S.A.	N/A
Recruiting	Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel NCT06737666	Xiyuan Hospital of China Academy of Chinese Medical Sciences	Phase 1
Unknown	Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) NCT05687435	Mei Han	Phase 2 / Phase 3
Unknown	Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients NCT05593367	Second Affiliated Hospital of Xi'an Jiaotong University	—
Unknown	Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D NCT05369884	Xiyuan Hospital of China Academy of Chinese Medical Sciences	EARLY_Phase 1
Completed	Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea NCT03977155	Boston Pharmaceuticals	Phase 2
Completed	Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D NCT03099785	Cosmo Technologies Ltd	Phase 2
Unknown	Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) NCT04095988	University of Ulm	N/A
Completed	Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance NCT02728063	PiLeJe	N/A
Completed	Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome NCT02538692	Chengdu University of Traditional Chinese Medicine	Phase 2 / Phase 3
Completed	Special Drug Use Surveillance of Irribow in Female Patients NCT02612649	Astellas Pharma Inc	—
Terminated	Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D NCT02239926	Mayo Clinic	Phase 2 / Phase 3
Completed	Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth NCT02251483	Cedars-Sinai Medical Center	N/A
Withdrawn	Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome NCT02190526	Tehran University of Medical Sciences	Phase 4
Completed	Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS NCT02358694	Connecticut Children's Medical Center	N/A
Completed	Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IB NCT02163213	Mayo Clinic	N/A
Completed	Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids NCT02111603	Mayo Clinic	Phase 4
Completed	A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) NCT01896583	Seldar Pharma, Inc.	Phase 2
Completed	A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowe NCT01870895	Astellas Pharma Inc	Phase 3
Completed	A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome NCT01736423	Astellas Pharma Inc	Phase 3
Unknown	The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome NCT01637714	Seoul National University Hospital	N/A
Completed	Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial NCT01350570	Chengdu University of Traditional Chinese Medicine	Phase 2 / Phase 3
Unknown	The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome NCT01373034	Seoul National University Hospital	N/A
Completed	Glutamine for the Treatment of Patients With Irritable Bowel Syndrome NCT01414244	Tulane University	Phase 2
Terminated	Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg NCT01358708	Forest Laboratories	Phase 3
Completed	Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) NCT01100684	Tioga Pharmaceuticals	Phase 3
Completed	Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome NCT01094041	Mayo Clinic	N/A
Completed	Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS) NCT00616200	University of North Carolina, Chapel Hill	N/A